OpenAlex · Aktualisierung stündlich · Letzte Aktualisierung: 14.03.2026, 14:33

Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.

AI's Inroad into Medication Enhancement

2025·0 Zitationen·BENTHAM SCIENCE PUBLISHERS eBooks
Volltext beim Verlag öffnen

0

Zitationen

5

Autoren

2025

Jahr

Abstract

AI and pharmaceutical improvement crossroads are an incredible opportunity in healthcare that can transform drug discovery, development, and delivery. AI-based approaches such as predictive modeling, pattern recognition, and mining of biomedical literature are some of the methodologies that can be accelerated for the identification of promising drug candidates. AI empowers drug design and synthesis by analyzing unstructured data and representing complex biological systems–such as protein folding. Automated laboratory processes (i.e., drug testing or synthesis) lead to faster and more efficient cycles of research. Virtual screening, de novo drug design, and repurposing existing drugs are some of the ways AI applications can help in medication to result in more precise and effective therapies. Predictive analysis facilitates the evaluation of treatment responses whereas real-time monitoring systems guarantee the safety of drugs via early detection of adverse drug reactions. Targeted drug delivery systems enhance drug delivery and effectiveness, leading to better patient outcomes. Such advancements not only accelerate the exploration of drug discovery but also lead to better diagnostic accuracy, patient safety, and resource distribution to give rise to an economical health care model. However, the application of AI for drug development has its obstacles, including concerns about data privacy, ethics, and transparency in AI algorithms. To unlock the full potential promise of AI in healthcare, these roadblocks must be overcome. The next steps are further streamlining of AI algorithms to improve precision, greater incorporation of AI in clinical decision support, and the development of regulatory frameworks to ensure the safe and ethical use of AI across various facets of patient care. In this paper, we briefly outline how AI has transformed aspects of medication enhancement from the perspective of benefits to patient-oriented care; and express how its current challenges will nevertheless facilitate advances and opportunities in the future of healthcare.

Ähnliche Arbeiten